Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Correction: Nuvectis Announces Marketing Approval of Ciprocopan in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Ciprocopan Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Juno Industries Announces Expanded Market Focus to Include International Opportunities, Leading with Indo-Pacific
